Navigation Links
Spherix Recruiting New 'Independent' Director to Regain NASDAQ Compliance

BETHESDA, Md., April 27 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that on April 23, 2009, it received written notification from NASDAQ that the Company was not currently in compliance with NASDAQ's independent director rule. Spherix fell out of compliance following the death of the Company's Chairman, A. Paul Cox, Jr., an event that reduced the number of "Independent" directors to below the required ratio. Per the rules of this requirement, NASDAQ has provided Spherix a cure period and the Company must regain compliance on or before the date of its next annual shareholders' meeting, or by April 13, 2010 should the meeting occur after October 12, 2009.

"Several promising candidates have already been identified," said Dr. Claire Kruger, Chief Executive Officer of Spherix. "One of the most important considerations in selecting this candidate will be determining whether we believe his or her experience will benefit the Company as we prepare for the potential commercialization of Naturlose(R) as a treatment for type 2 diabetes. We anticipate making a decision prior to the fall Annual Shareholders Meeting and well within the cure period NASDAQ has provided us."

The listing rule requires that a majority of the board of directors be composed of independent directors. To regain compliance, the Company needs to fill the current vacancy with an independent director or request one of the non-independent directors to resign before the end of the cure period provided by NASDAQ. If the Company fails to regain compliance with the independent director rule within the above time frame, NASDAQ will provide notice to the Company that its common stock will be delisted from NASDAQ. If the Company receives such a letter, the Company will have an opportunity to appeal the determination.

About Spherix

Spherix Incorporated was launched in 1967 as a scientific research company, under the name Biospherics Research. The company now leverages its scientific and technical expertise and experience through its two subsidiaries -- Biospherics Incorporated and Spherix Consulting, Inc. Biospherics is currently running a Phase 3 clinical trial to study the use of Naturlose as a treatment for Type 2 diabetes. Its Spherix Consulting subsidiary provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. For more information, please visit

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop Naturlose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Spherix Reports 3rd Quarter Earnings
3. Spherix Reports 2007 Financial Results
4. Spherix Hires Key Employees
5. Spherix Holds Annual Shareholders Meeting
6. Spherix Reports 1st Quarter Earnings
7. Spherix Receives NASDAQ Bid Price Deficiency Letter
8. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
9. Spherix Transfers Stock Listing to Nasdaq Capital Market
10. Spherix Reports 3rd Quarter Earnings
11. Spherix Announces 2008 Financial Results
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ... join physicians, aesthetic practitioners and aesthetics professionals from Central America and abroad for ... held in Panama City, Panama Feb. 17-19, 2016. Testart will present and discuss ...
(Date:11/30/2015)... Dec. 1, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... joined the American Business Act on Climate Pledge, alongside more ... standing with the Obama Administration to demonstrate an ongoing commitment ... outcome to the COP21 Paris climate ... Sarnia, Canada . --> BioAmber ...
(Date:11/30/2015)... , Nov. 30, 2015 Spherix ... company committed to the fostering and monetization of ... current and prospective initiatives designed to create shareholder ... Executive Officer of Spherix. "Based on published reports, ... licensees exceeds $50 billion and Spherix will seek ...
(Date:11/30/2015)... -- HUYA Bioscience International, the leader in accelerating global development ... announced it has signed a Memorandum of Understanding with ... between KDDF and HUYA with the ultimate goal of ... the global market. China,s ... preclinical and clinical stage compounds. The company advances the ...
Breaking Biology Technology:
(Date:11/20/2015)... 2015 NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... was recently interviewed on The RedChip Money Report ... weekend on Bloomberg Europe , Bloomberg Asia, Bloomberg ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:11/18/2015)... 2015  As new scientific discoveries deepen our understanding ... healthcare providers face challenges in better using that knowledge ... addition, as more children continue to survive pediatric cancer, ... old age. John M. Maris, M.D ., ... Philadelphia (CHOP) . --> John M. ...
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
Breaking Biology News(10 mins):